Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | PTGIR | P43119 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8727056 | 0.93 | BCHE (0.44) | BCHENPY1RPTGIRTBXA2RNR1H4 | |
| SCHEMBL7754987 | 0.80 | BCHE (0.46) | BCHENPY1RPTGIRNR1H4CARM1 | |
| SCHEMBL9034346 | 0.79 | BCHE (0.39) | BCHECARM1PRMT6 | |
| SCHEMBL20907004 | 0.76 | SIGMAR1 (0.51) | BCHE | |
| SCHEMBL28087406 | 0.75 | KCNK3 (0.37) | TBXA2RHRH3 | |
| SCHEMBL15467458 | 0.74 | SLC6A2 (0.41) | — | |
| SCHEMBL10486946 | 0.74 | LMNA (0.46) | — | |
| SCHEMBL9352867 | 0.73 | CARM1 (0.54) | BCHEPTGIRCARM1PRMT6FFAR4 | |
| SCHEMBL9535263 | 0.72 | CARM1 (0.52) | BCHENPY1RCARM1PRMT6FFAR4 | |
| Bepotastine SCHEMBL29459 | 0.71 | BCHE (0.55) | BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9849121-B2 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2017-12-26 | — | — | US | disclosed |
| US-20170027863-A1 | ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BEPOTASTINE | LUPIN LTD (IN) | 2017-02-02 | — | — | US | disclosed |
| CN-104003978-B | The industrialized process for preparing of bepotastine or its racemoid | JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD. (CN) | 2016-01-20 | — | — | CN | disclosed |
| EP-2624836-B1 | BEPOTASTINE COMPOSITIONS | BAUSCH & LOMB (US) | 2015-09-23 | — | — | EP | disclosed |
| US-20150031724-A1 | AQUEOUS LIQUID PREPARATIONS AND LIGHT-STABILIZED AQUEOUS LIQUID PREPARATIONS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8883825-B2 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8877168-B1 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations | SENJU PHARMACEUTICALS CO., LTD. (JP) | 2014-11-04 | — | — | US | disclosed |
| EP-2670387-A1 | ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BEPOTASTINE | Lupin Limited (IN) | 2013-12-11 | — | — | EP | disclosed |
| EP-2624836-A2 | BEPOTASTINE COMPOSITIONS | Bausch & Lomb Incorporated (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20130046240-A1 | BEPOTASTINE COMPOSITIONS | BAUSCH HEALTH AMERICAS, INC. | 2013-02-21 | — | — | US | disclosed |
| US-20120322825-A1 | AQUEOUS LIQUID PREPARATIONS AND LIGHT-STABILIZED AQUEOUS LIQUID PREPARATIONS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2012-12-20 | — | — | US | disclosed |
| WO-2012104818-A1 | ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BEPOTASTINE | LUPIN LIMITED (IN) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012048059-A2 | BEPOTASTINE COMPOSITIONS | ISTA PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130046240-A1 | BEPOTASTINE COMPOSITIONS | WASF2, NOTUM, WEE1 | BCHE 25/4885NPY1R 4822/4885PTGIR 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.